Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Jan 15. pii: jrheum.171469. doi: 10.3899/jrheum.171469. [Epub ahead of print]

2.

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL.

J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15.

3.

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.

Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, Pinto-Correia A, Otawa S, Lopez-Romero P, de la Torre I, Macias W, Rooney TP, Smolen JS.

Ann Rheum Dis. 2019 Feb;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271. Epub 2018 Sep 7.

4.

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22.

PMID:
30058112
5.

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.

J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11.

6.

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.

Tuttle KR, Brosius FC 3rd, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Tanaka Y, Haneda M, Liu J, Silk ME, Cardillo TE, Duffin KL, Haas JV, Macias WL, Nunes FP, Janes JM.

Nephrol Dial Transplant. 2018 Nov 1;33(11):1950-1959. doi: 10.1093/ndt/gfx377.

7.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20.

8.

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS.

Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489.

9.

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.

Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R.

Clin Pharmacol Ther. 2018 Aug;104(2):364-373. doi: 10.1002/cpt.936. Epub 2017 Dec 8.

PMID:
29134648
10.

Inside the Mind of the Online Health Information Searcher using Think-Aloud Protocol.

Macias W, Lee M, Cunningham N.

Health Commun. 2018 Dec;33(12):1482-1493. doi: 10.1080/10410236.2017.1372040. Epub 2017 Sep 27.

PMID:
28952804
11.

Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Zhang X, Chua L, Ernest C 2nd, Macias W, Rooney T, Tham LS.

CPT Pharmacometrics Syst Pharmacol. 2017 Dec;6(12):804-813. doi: 10.1002/psp4.12251. Epub 2017 Oct 17.

12.

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.

Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T, Macias W.

Mod Rheumatol. 2018 Jan;28(1):20-29. doi: 10.1080/14397595.2017.1307899. Epub 2017 Apr 25.

PMID:
28440680
13.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.

N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.

14.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

15.

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T.

Arthritis Rheumatol. 2017 Mar;69(3):506-517. doi: 10.1002/art.39953.

16.

Baricitinib in Patients with Refractory Rheumatoid Arthritis.

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS.

N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.

17.

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.

Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W.

J Rheumatol. 2016 Mar;43(3):504-11. doi: 10.3899/jrheum.150613. Epub 2016 Feb 1. Erratum in: J Rheumatol. 2016 May;43(5):998.

18.

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.

Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM.

Br J Dermatol. 2016 Jun;174(6):1266-76. doi: 10.1111/bjd.14403. Epub 2016 Apr 5.

PMID:
26800231
19.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC.

Ann Rheum Dis. 2015 Feb;74(2):333-40. doi: 10.1136/annrheumdis-2014-206478. Epub 2014 Nov 27.

20.

An alcohol message beneath the surface of ER: how implicit memory influences viewers' health attitudes and intentions using entertainment-education.

Kim K, Lee M, Macias W.

J Health Commun. 2014;19(8):876-92. doi: 10.1080/10810730.2013.837556. Epub 2014 Jan 30.

PMID:
24479746
21.

Drotrecogin alfa (activated) in severe sepsis.

Janes JM, Vangerow B, Costigan TM, Macias WL.

Lancet Infect Dis. 2013 Feb;13(2):108-9. doi: 10.1016/S1473-3099(12)70309-2. No abstract available.

PMID:
23347626
22.

Drotrecogin alfa (activated) in adults with septic shock.

Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group.

N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22.

23.

[Collaboration strategies for the Iberoamerican Cardiovascular Journals network].

Márquez MF, Heras M, Del Pilar-Aguilar M, Alfonso F, Arai K, Barrero C, Belzeti C, Berman S, Coromoto N, Cuesta A, Guzmán I, Lombana BM, López Santi R, Lucas-Luciardi H, Macías W, Moreira F, Paniagua M, Pérez-de Isla L, Reyes Caorsi W, Salvati A.

Arch Cardiol Mex. 2011 Jul-Sep;81(3):273-6. Spanish. No abstract available.

PMID:
21975243
24.

Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.

Riesmeyer JS, Salazar DE, Weerakkody GJ, Ni L, Wrishko RE, Ernest CS 2nd, Luo J, Li YG, Small DS, Rohatagi S, Macias WL.

J Clin Pharmacol. 2012 Jun;52(6):789-97. doi: 10.1177/0091270011406280. Epub 2011 May 31.

PMID:
21628601
25.

Activated protein C and acute kidney injury: Selective targeting of PAR-1.

Gupta A, Williams MD, Macias WL, Molitoris BA, Grinnell BW.

Curr Drug Targets. 2009 Dec;10(12):1212-26. Review.

PMID:
19715537
26.
27.

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L.

J Clin Pharmacol. 2009 Aug;49(8):984-98. doi: 10.1177/0091270009337942. Epub 2009 Jun 22.

PMID:
19546250
28.

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS.

Circulation. 2009 May 19;119(19):2553-60. doi: 10.1161/CIRCULATIONAHA.109.851949. Epub 2009 May 4.

PMID:
19414633
29.

Cytochrome p-450 polymorphisms and response to clopidogrel.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS.

N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.

30.

Strengthening the safety net for online seniors: factors influencing differences in health information seeking among older internet users.

McMillan SJ, Macias W.

J Health Commun. 2008 Dec;13(8):778-92. doi: 10.1080/10810730802487448.

PMID:
19051113
31.

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

Crit Care. 2008;12(5):R117. doi: 10.1186/cc7011. Epub 2008 Sep 11.

32.

Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock.

Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, Macias WL, Williams MD.

Am J Respir Crit Care Med. 2008 Aug 1;178(3):276-82. doi: 10.1164/rccm.200801-131OC. Epub 2008 May 29.

33.
34.

The return of the house call: the role of internet-based interactivity in bringing health information home to older adults.

Macias W, McMillan S.

Health Commun. 2008;23(1):34-44. doi: 10.1080/10410230701805174.

PMID:
18443991
35.

Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.

Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S390-9.

PMID:
17940975
36.
37.

Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.

Chawla LS, Seneff MG, Nelson DR, Williams M, Levy H, Kimmel PL, Macias WL.

Clin J Am Soc Nephrol. 2007 Jan;2(1):22-30. Epub 2006 Dec 13.

38.

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.

Williams MD, Macias W, Rustige J.

Intensive Care Med. 2007 Aug;33(8):1487-8; author reply 1489-91. Epub 2007 Jun 12. No abstract available.

PMID:
17563878
39.

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

PMID:
17556722
40.

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL.

J Crit Care. 2007 Jun;22(2):142-52. Epub 2007 Jan 31.

PMID:
17548026
41.

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

Lancet. 2007 Mar 10;369(9564):836-843. doi: 10.1016/S0140-6736(07)60411-5.

PMID:
17350452
42.

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.

Shorr AF, Bernard GR, Dhainaut JF, Russell JR, Macias WL, Nelson DR, Sundin DP.

Crit Care. 2006;10(3):R92. Epub 2006 Jun 15.

43.
44.
45.

Activated protein C: do more survive?

Macias WL.

Intensive Care Med. 2006 Apr;32(4):605-7; author reply 610-2. Epub 2006 Mar 1. No abstract available.

PMID:
16508756
46.

Management of early acute renal failure: focus on post-injury prevention.

Bellomo R, Bonventre J, Macias W, Pinsky M.

Curr Opin Crit Care. 2005 Dec;11(6):542-7. Review.

PMID:
16292057
47.

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.

Macias WL, Nelson DR, Williams M, Garg R, Janes J, Sashegyi A.

Crit Care. 2005;9(6):R607-22. Epub 2005 Sep 22. Review.

48.

Pleuritic chest pain and exertional dyspnea.

Macias WL, Kabrhel C, Nadel ES, Brown DF.

J Emerg Med. 2005 Nov;29(4):467-73. No abstract available.

PMID:
16243209
49.

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.

Crit Care Med. 2005 Oct;33(10):2266-77.

PMID:
16215381
50.

Early changes in organ function predict eventual survival in severe sepsis.

Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD.

Crit Care Med. 2005 Oct;33(10):2194-201.

PMID:
16215369

Supplemental Content

Loading ...
Support Center